Efficacy of PD-1 inhibitor combined with radiotherapy in advanced and relapsed / refractory extranodal NK/T cell lymphoma
10.3760/cma.j.cn113030-20230729-00026
- VernacularTitle:PD-1抑制剂联合放疗治疗晚期及复发难治性NK/T细胞淋巴瘤疗效
- Author:
Yuan LIU
1
;
Wenyue XIE
;
Quan LI
;
Hanyu WANG
;
Yunfei XIA
;
Yujing ZHANG
Author Information
1. 湖北文理学院附属医院 襄阳市中心医院肿瘤科，襄阳 441000
- Keywords:
Lymphoma, extranodal NK-T-cell;
Programmed death-1 inhibitor;
Radiotherapy;
Combination therapy
- From:
Chinese Journal of Radiation Oncology
2024;33(5):426-431
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To assess the efficacy and safety of programmed death-1 (PD-1) inhibitor combined with radiotherapy in advanced and relapsed / refractory extranodal NK/T cell lymphoma (ENKTL).Methods:Clinical data of 26 patients with advanced and recurrent / refractory ENKTL admitted to Sun Yat-sen University Cancer Center from January 2019 to December 2021 were retrospectively analyzed. All patients were treated with the PD-1 inhibitor combined with radiotherapy. The treatment responses, survival rate and and adverse reactions of the regimen were analyzed. The Kaplan-Meier method was used to estimate the 1- and 2-year progression-free survival (PFS) rate and overall survival (OS) rate, and the Cox proportional risk model was used for univariate prognostic factorial analysis for PFS and OS.Results:The median follow-up time of 26 patients was 29 months (10-49 months). The objective response rate (ORR) was 85%. The complete and partial remission rates were 77% and 8%. The median PFS time was 25 months. The 1- and 2- year PFS rates were 73.1% and 53.3%. The 1- and 2- year OS rates were 88.5% and 75.3%. The main adverse reaction was acute mucositis with an incidence rate of 31% (8/26), followed by hematological toxicity. The incidence of immune-related adverse events in lung, liver and thyroid were low. Only 1 patient developed grade 3 acute mucositis, 1 patient developed grade 4 immune pneumonitis, and the remaining patients had grade 1-2 toxicities. All patients showed good tolerance. The univariate analysis showed that elevated lactate dehydrogenase, Epstein-Barr virus DNA positive after treatment, and less than 6 cycles of anti-PD-1 immunotherapy were prognostic factors for poor OS.Conclusion:The regimen of PD-1 inhibitor combined with radiotherapy demonstrates promising efficacy and well tolerance in patients with advanced and relapsed / refractory ENKTL.
